Administrative Rules of Montana
Department 24 - LABOR AND INDUSTRY
Chapter 24.177 - BOARD OF PHYSICAL THERAPY EXAMINERS
Subchapter 24.177.7 - Topical Medication Rules
Rule 24.177.704 - TOPICAL MEDICATION PROTOCOLS
Universal Citation: MT Admin Rules 24.177.704
Current through Register Vol. 18, September 20, 2024
(1) The following protocols apply to each classification and following list of topical medications for which a prescription is required under state or federal law:
(a) bactericidal agents:
(i) action: interferes with functions of the
cell wall membrane;
(ii)
indication: topical treatment for dermal infections; and
(iii) contraindications: hypersensitivity to
the specific substance, concurrent use of curariform muscle relaxants and other
relaxants and other neurotoxic drugs. Consult the current Physicians Desk
Reference (PDR) for further specifics.
(b) debriding agents:
(i) action: cleanse the surface of wounds of
wound exudate, bacteria, and particulate contaminants;
(ii) indication: cleanse exudative wounds
such as venous stasis ulcers, decubitus ulcers, infected traumatic and surgical
wounds, and infected burns; and
(iii) contraindications: debriding enzymes,
should be used with precaution against allergic reactions, particularly in
patients hypersensitive to materials of bovine origin or to mercury compounds.
Consult the current PDR for specifics.
(c) anesthetic agents:
(i) action: blocks both the initiation and
conduction of nerve impulses by decreasing the neuron membranes permeability to
sodium ions;
(ii) indication:
relieve pain and inflammation associated with minor skin disorders and for
acute inflammatory conditions; and
(iii) contraindications: sensitivity to the
topical anesthetic, local infections at the site of application, and skin
disorders, severe or extensive, especially if the skin is abraded or broken.
Consult the current PDR for specifics.
(d) anti-inflammatory agents (see
adrenocortico-steroids).
(e)
antispasmodic agents:
(i) action: forms
strong drug-receptor complex at postganglionic parasympathetic neuroeffector
sites in smooth muscle, cardiac muscle and exocrine glands, thereby blocking
action of acetylcholine;
(ii)
indication: reduce the volume of perspiration by inhibiting sweat gland
secretions; and
(iii)
contraindications: some commercially available formulations may contain a
sulfite that can cause allergic-type reactions in certain susceptible
individuals. Consult the current PDR for specifics.
(f) adrenocortico-steroids:
(i) action: diffuses across cell membranes to
complex with specific cytoplasmic receptors. The resulting complexes enter the
nucleus, bind to DNA thereby irritating cytoplasmic synthesis of enzymes
responsible for systemic effects of adrenocortico-steroid;
(ii) indication: anti-inflammatory (bursitis,
tendonitis, myositis, arthritis), antipruritic and vasoconstrictor actions;
and
(iii) contraindications:
special care must be exercised when these agents are used in children, growing
adolescents, and pregnant women. Intolerance to adrenocortico-steroids,
infection present at the treatment site not controlled by antibiotics,
prolonged use, large areas, and occlusive dressings. Consult the current PDR
for specifics.
(2) The board considers anti-fungal agents to be within the class of bactericidal agents.
37-11-107, 37-11-201, MCA; IMP, 37-11-106, 37-11-107, MCA;
Disclaimer: These regulations may not be the most recent version. Montana may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.